Background: Molecular markers are currently being utilized as sensitive prognosticators of cancer patient outcome.
introduction
Sensitive prognostication systems are useful for individual physicians and multidisciplinary teams who manage soft tissue sarcoma (STS). Indeed, robust and reproducible staging criteria enable accurate estimation of prognosis that may aid in selecting appropriate therapies. Current staging approaches such as the American Joint Committee on Cancer staging system and the STS nomogram are based on clinical, radiological, and pathological factors identified as significant in STS local recurrence, distant metastasis, and tumor-related mortality [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, such staging systems are generally crude, exhibiting limited ability to distinguish between STS tumors of similar histological subtype, size, grade, and location, whose individual outcome may vary significantly notwithstanding similar or identical stage.
Lessons learned from other malignancies such as breast cancer indicate that inclusion of molecular prognostic variables (e.g. estrogen receptor and human epidermal growth factor receptor 2) may enhance staging systems by refinement in distinguishing between tumors possessing similar clinicopathological characteristics. High-throughput assays can identify potential DNA, RNA, or protein-level molecular prognosticators. Molecules affecting tumorigenicity and metastasis could be particularly valuable in predicting STS patient outcomes and might even serve as potential therapeutic targets.
Studies of STS molecular prognosticators are limited by the rarity of these mesenchymal-origin malignancies, representing <1% of all adult solid cancers [14] . STS rarity results in limited human tumor specimens available for analysis; the reality that STS encompasses >50 distinct histological subtypes further limits such studies [15] . In general, STS can be classified into two major subgroups: those with simple karyotypes and specific genetic alterations (translocations or point mutations) and those with complex, unbalanced aneupliod karyotypes [14] , including two very common STS subtypes: leiomyosarcoma and malignant fibrous histiocytoma (MFH) [undifferentiated pleomorphic sarcoma (UPS)]. While insights into molecular deregulations occurring in the first group might enhance identification of prognostic factors (e.g. c-Kit in gastrointestinal stromal tumors), the complexity of STS of the latter group hampers such advances.
A large clinically annotated tissue microarray (TMA) from STS surgical specimens was constructed to bridge this knowledge gap enhancing identification of possible molecular outcome predictors in complex karyotype STS patients. Several biomarkers of STS progression were evaluated for their ability to independently predict patient outcome [11, [16] [17] [18] [19] [20] .
materials and methods clinically annotated TMA construction
This study was conducted with institutional review board approval. A prospective STS clinical database including patients with primary STS who underwent complete resection with either negative or positive microscopic margins (R0/R1 resection) at the University of Texas MD Anderson Cancer Center (UTMDACC) was searched to identify cases for which formalinfixed paraffin-embedded blocks were available. The histological diagnosis of STS was confirmed by a UTMDACC sarcoma pathologist (AJL). Only blocks consisting of sufficient viable tumor were allocated to eventual TMA construction, resulting in 205 appropriate human specimens. The initial database was then modified and a study-specific clinical database was created for the selected specimens.
For TMA construction, hematoxylin-eosin (H&E)-stained sections of the 205 STS tumor blocks were reviewed by a sarcoma pathologist (AJL), and areas of homogeneous, viable tumor were identified. Using an automated TMA apparatus (ATA-27; Beecher Instruments, Sun Prairie, WI), 0.6-mm punch samples were obtained from the donor tissue blocks. The selected tissue cores were formatted into a standard 4.5 · 2 · 1 cm 3 recipient block.
Two tissue cores were taken for each case. Two TMA blocks containing a total of 410 STS cores were constructed. Sections (4 lm) were cut, and one standard H&E-stained slide was examined to verify the presence of viable tumor.
immunohistochemistry
Commercially available antibodies against p53 (clone DO7; Dako, Carpinteria, CA), matrix metalloproteinase (MMP) 2 (clone 42-5D11; Chemicon/Millipore, Billerica, MA), MMP9 (mAb-3; Oncogene Research Products, Boston, MA), Ki-67 (clone MIB-1; Dako), epidermal growth factor receptor (EGFR) (clone 31G7; Zymed, Carlsbad, CA), BCL-2 (clone 100; Biogenix, San Ramon, CA), BCL-X (clone 2H12; Invitrogen, Carlsbad, CA), and b-catenin (clone 14; BD Biosciences, San Jose, CA) were used for immunohistochemistry. Briefly, 4-lm-thick sections were prepared from formalin-fixed paraffin-embedded TMA tissue blocks and were dried in a 60°C oven for 20 min. These sections were placed in an automated Bond Max stainer that pretreated the slides with enzyme-induced epitope retrieval for 2 min, followed by incubation with antibodies against b-catenin (clone 14, dilution 1 : 500; BD Biosciences). Anti-mouse secondary antibody and the Refine Polymer Detection Kit (Leica, Wetzlar, Germany) were used for immunostaining, with 3,3-diaminobenzidine serving as chromagen. Positive and negative controls were run in parallel.
immunohistochemistry staining scoring methodology
The Genetix/Applied Imaging Ariol image analysis instrument (San Jose, CA) was used to quantify TMA samples' immunoreactivity. This system allows determination of tumor areas immunoreactivity along a continuous scale within multiple registers of intensity; moreover, the total number of nuclei and total number of reactive nuclei can be determined. To summarize this process, the entire stained immunohistochemical slide is scanned at ·50. An overlay template map is constructed containing the identifier for each individual core sample electronically placed over the original scan (Figure 1 ), allowing data from each sample to be tracked with the core sample identifier for subsequent statistical analysis. Each individual sample was examined by a sarcoma pathologist (AJL or WLW), areas of viable tumor were selected and joined together, and unwanted areas (i.e. nonviable tumor, stroma, lymphocytes or tissue, or staining artifacts) were excluded, thereby creating a total combined tumor area of the two cores from each tumor sample for quantification of immunoreactivity. For determination of cytoplasmic reactivity, the system was iteratively trained to recognize the total tumor cellular cytoplasm and convert this to an area measurement. The system was then taught, under the guidance of a pathologist, to recognize areas of the tumor as having weak, intermediate, or strong reactivity for an immunohistochemical chromagen, optimized for each individual stain. Data were electronically acquired as total staining area for each intensity range; results were ultimately expressed as percentage reactivity for weak, moderate, strong, or negative based on total cytoplasmic space to normalize for variations in evaluable tumor area from each sample. For nuclear reactivity, shape and color quantifiers were used to determine the total number of tumor and reactive nuclei; data were expressed as percentagepositive nuclei. All samples were assessed by a pathologist to ensure that Ariol system-produced data were compatible with human visual assessment; 10%-15% of samples were comprehensively assessed by actual counting of nuclei in a defined area or approximating the various levels of reactivity using a grid for comparison to the computer-generated data.
statistical analysis
Estimates of overall survival (OS) curves were calculated according to Kaplan-Meier (KM) product-limit methods and were calculated from the date of diagnosis of the primary disease to the event date or last follow-up if censored. Cox proportional hazards models were utilized to assess for associations between independent variables and OS. All TMA markers were first examined in continuous form. Martingale residual plots were used to examine the linearity of Cox models and to determine whether there were natural cut-off points for marker categorization. Estimates of cumulative incidence of local recurrence, distant recurrence, and OS were calculated by the method of Gooley et al. [21] using a publicly available SAS macro created by Erik Bergstralh of the Mayo Clinic. The figures were generated using S-PLUS. One-, 2-, and 5-year cumulative incidence event rates and the overall differences in local recurrence incidence between groups were estimated by subdistribution analysis of competing risks [22] using the 'cmprsk' R package. We analyzed the cause-specific hazard function for local recurrence. Each independent variable was first examined separately in a univariable Cox proportional hazards model with competing risk using the stacked dataset technique [23] . All univariable Cox models were fitted with all possible data points. For all outcomes, only the independent variables that had P values of £0.10 in the univariable Cox model analyses were examined in multivariable Cox models.
results

study population
A total of 205 primary complex karyotype STS patients who had complete macroscopic resection (R0/R1 resection) at UTMDACC comprised the study cohort. Table 1 (Figure 2 ). Markers were selected to represent several protumorigenic, prometastatic processes such as proliferation (nuclear Ki67), antiapoptosis (BCL-2 and BCL-X), and migration and invasion (nuclear and cytoplasmic MMP2 and MMP9). Other markers (nuclear p53, EGFR, and nuclear and total b-catenin) previously shown to be expressed and/or to play a potential role in STS progression were also included. Most evaluated markers were expressed by >70% of samples (Table 2 ). MMP2 and MMP9 were expressed by 80% of the samples, p53 and ki67 by 50%, whereas only one-third of the samples expressed nuclear b-catenin. The expression of each marker was further determined as low or high if level was below or above individual staining mean expression level, respectively; high versus low percentage of cells expressing each marker within STS samples is depicted in Table 2 .
univariable and multivariable analysis
Sixty-seven patients in the study cohort died during follow-up; clinical, pathological, and molecular variables were evaluated for their correlation with OS using KM curves. Figure 3 (Table 3B) . Percentage of tumor cells expressing MMP2, >10% versus £10%, remained an independent molecular predictor (adjusted HR 1.74; 95% CI 1.02-2.97, P = 0.04).
Complex karyotype STS are considered to have a propensity for local recurrence. In the current series, local failure occurred in 24 (11.7%) patients. Thirteen (9.7%) recurrences occurred following a microscopic negative resection and 11 (17.7%) after a positive microscopic resection; no statistical difference was noted between these two cohorts (P = 0.13). Our data analysis demonstrates that older age (HR 1.40, P = 0.02) and nonextremity location (HR 3.07, P = 0.02) were clinical predictors of STS local recurrence whereas gender, tumor size, grade, depth, and the quality of surgery (R0 versus R1) did not emerge as significant risk factors to local recurrence (Table 3A) . Of all markers, higher total MMP2 expression by tumor cells (evaluated as a continuous variable) significantly increased the risk for STS local recurrence (HR 6.56, P = 0.008). Higher expression of nuclear MMP2 was also associated with increased recurrence rate (HR 5.06, P = 0.02), and high nuclear p53 Figure 1 . Automated scoring of immunohistochemistry on the tissue microarray. In panel (A), immunostaining for MMP2 is illustrated. The artifact in the upper left portion (shaded and hatched) was excluded from the analysis. The inset at the lower right demonstrates the measured levels of this cytoplasmic stain where blue is negative and yellow, orange, and red represent low, median, and high intensity of staining, respectively. Each of these is quantified separately as a defined area and then normalized to the total measured area to allow comparison between samples. In panel (B), the sample is stained for p53. The inset box shows how each nucleus is pseudocolored to define it as positive (red) or negative (blue), counted, and then normalized to the total number of nuclei in the sample.
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Cumulative incidence plots demonstrated that higher expression levels of nuclear MMP2 correlated with local recurrence (P = 0.03; Figure 3 ); 1-, 2-, and 5-year cumulative incidence of local recurrence for patients expressing nuclear MMP2 of >20% versus £20% of analyzed tumor cells were 9.8% [standard deviation (SD) 4.2], 15.7% (SD 2.2), and 23.5% (SD 6.4) versus 5.5% (SD 2), 6.3% (SD 2.2), and 9.7% (SD 4.2), respectively. One-, 2-, and 5-year cumulative incidence of local recurrence for patients expressing p53 of >15% versus £15% of analyzed tumor cells were 9.2% (SD 3.3), 14.9% (SD 4.2), and 18% (SD 4.7) versus 5.4% (SD 2.4), 5.4% (SD 2.4), and 12% (SD 4.3), respectively. On multivariable Cox proportional hazards model analysis, older age (HR 1.52, P = 0.008), nonextremity location (HR 4.1, P = 0.005), and higher MMP2 expression by >10% of tumor cells (HR 6.28, P = 0.006) emerged as independent prognosticators (Table 3B) .
We further evaluated whether high total MMP2 expression (>10%) correlates with higher nuclear MMP2 expression levels (>20%); 37.6% (n = 38) of tumors with low total MMP2 expression level expressed high nuclear MMP2 versus 91% of tumors with high total MMP2 expression level (P < 0.0001).
discussion
Reliable molecular predictive factors are essential for an improved stratification of complex karyotype STS patients into useful staging categories. Due to the rarity of these tumors, only few studies have examined the potential prognostic value of molecular markers in complex karyotype STS, utilizing relatively small sample cohorts [11, 17, 24] . In this study, we evaluated several contemporary clinicopathological prognostic indicators as well as multiple potential molecular markers as predictors of outcome in 205 complete macroscopic resection (R0/R1 resection) STS patients using a clinically annotated TMA. This relatively homogenous cohort consists mostly MFH and unclassified STS of the extremity (77%), which are frequently encountered at our institution possibly reflecting a referral bias to the MD Anderson Cancer Center. Our results indicate that the STS TMA is a useful bio-resource that can establish and/or confirm the expression of novel molecular markers identified in other preclinical studies. TMAs are a powerful research tool capable of simultaneously processing large numbers of tumor specimens to detect expression levels of multiple proteins using immunohistochemical analysis as is commonly accepted in clinical practice. Furthermore, the use of an automated scoring apparatus enables a more objective, quantitative, and observerindependent means of acquiring staining result measurements. The TMA created for the current study was relatively homogenous, consisting predominately of large (>5 cm), extremity, and high-grade UPS, one of the most commonly encountered STS clinical contexts. Our data show that expression of most candidate molecular markers examined in this series was detectable in >70% of STS tumor tissues; however, only MMP2 expression correlated with OS whereas both MMP2 and p53 expression correlated with local recurrence.
Increased expression of MMPs has been associated with more advanced disease [25] [26] [27] as well as with shortened patient 
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survival in a variety of epithelial malignancies [28] [29] [30] [31] [32] . Benassi et al. [33] previously reported that high MMP2 expression levels but not MMP9 correlated with higher grade and shorter disease-free survival in a series of 73 STS patients. Utilizing a larger cohort of STS patients, our results confirm these data; MMP2 expression by >10% of analyzed tumor cells remained an independent predictor of both local recurrence and OS in our multivariable analyses. MMP family consists of numerous proteases separable by substrate specificity, inhibitor, and extracellular membranebinding efficiency. MMPs are linked to various changes in cellextracellular matrix (ECM) interactions, dissociation of intercellular adhesion complexes, and degradation of ECM; all necessary for tumor cellular proliferation, invasion, angiogenesis, and metastasis [20, 34, 35] . MMP2 (also known as gelatinase A) is a 72-kDa type VI collagenase that degrades type IV collagen and fibronectin; its role in invasion and metastasis was previously reported in various cancers including osteosarcoma and STS [36, 37] . Due to its potential involvement in STS progression, angiogenesis, and metastasis, MMP2 should be assessed as a possible target for molecular therapy in high-grade complex karyotype STS.
Local recurrence following complete resection (R0/R1 resection) occurs in 20% of STS patients [13, 38] and is associated with worse outcomes [13, 39] . However, it is not clear whether local recurrence per se is causative of or is a marker of more aggressive biological behavior. None the less, STS local recurrence often results in significant morbidity or even mortality even in the absence of distant metastasis [40] . The total number of scorable specimens for each marker varied due to different rates of sample attrition. b Cut-offs for high-versus low-biomarker expression level in positively staining samples were defined according to the mean result as calculated by the Ariol system for each marker: nuclear p53 (15%), ki67 (10%), total MMP2 (10%), nuclear MMP2 (20%), total MMP9 (20%), nuclear MMP9 (55%), BCL-2 (10%), EGFR (2%), and cytoplasmic b-catenin (15%). Expression levels of BCL-X and nuclear b-catenin, as scored by the Ariol system, were very low in most cases and therefore these were excluded from our outcome analysis. MMP, matrix metalloproteinase; EGFR, epidermal growth factor receptor.
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Therefore, there is consensus that every effort should be made to avoid local recurrence. Some reports indicate that an aggressive surgical approach may decrease local recurrence and improve survival [13, 39, 41, 42] , possibly enhanced in selected STS by the addition of radiotherapy, or even isolated limb perfusion (ILP) [43] . However, these therapeutic modalities all have associated morbidity; because high-grade complex karyotype STS have differing propensities for local and/or distant recurrence, proper patient selection for individualized therapeutic approaches would be optimal. Our data analysis indicates that higher STS MMP2 expression levels is an independent predictor of STS local recurrence, implying that such patients may specifically benefit from a combined multimodality treatment which include a more aggressive surgical approach with radiation, and possible chemotherapy as indicated. Our results also indicate that higher STS p53 expression levels may correlate with more aggressive local behavior, supporting previous reports that have shown correlations between higher p53 expression and more aggressive osteosarcoma phenotypes [44] [45] [46] . Interestingly, Muret et al. [47] have recently demonstrated an association between higher p53 expression levels and a poorer STS response to ILP with tumor necrosis factor-a and melphalan, implying that p53 (and possibly other potential biomarkers) may also help to predict response to a specific therapy, thus enabling more individualized STS patient management. In summary, in spite of multimodality therapeutic approach, many STS patients will experience local recurrence and/or distant metastasis followed by death; hence, identification of clinical, pathological, and molecular prognosticators as well as molecular therapeutic targets is urgently needed. Here, we indicate that clinically annotated large-scale TMA may be utilized to initially identify such biomarkers, followed by further validation using large multi-institutional prospectively accrued STS patient cohorts of STS of sufficient power to establish these biomarkers as clinically relevant STS prognosticators. 
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